Filing Flows › Sunshine Biopharma (SBFM) › Q1 2026 › vs Q4 2025
Sunshine Biopharma (SBFM) Q1 2026 vs Q4 2025 (quarter over quarter)
Sunshine Biopharma's revenue fell $488K (-6%) from $8.6M in Q4 2025 to $8.1M in Q1 2026.
Sunshine Biopharma, Q1 2026: revenue $8.1M (-9% year over year), operating margin -17.3%, net loss $1.2M, operating cash flow −$2.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.1M | $8.6M | −$488K | -6% |
| Other income, net | $152K | $57K | $94K | +164% |
| Net loss | $1.2M | $2.1M | −$897K | -42% |
| Costs & expenses | $9.5M | $10.8M | −$1.3M | -12% |
| Operating costs | $9.5M | $10.4M | −$883K | -9% |
| Cost of revenue | $5.9M | $5.5M | $359K | +6% |
| Operating expenses | $3.6M | $4.8M | −$1.2M | -26% |
| Operating cash sources | $2.1M | $1.7M | $434K | +25% |
| Depreciation & amortization | $77K | $99K | −$22K | -22% |
| Cash used in operations | $2.1M | $1.6M | $456K | +28% |
| Net loss absorbed | $1.2M | $2.1M | −$897K | -42% |
| Working capital & other | $905K | −$426K | $1.3M | — |
Questions
How much did Sunshine Biopharma's revenue grow quarter over quarter in Q1 2026?
Sunshine Biopharma's revenue fell $488K (-6%) from $8.6M in Q4 2025 to $8.1M in Q1 2026.